Inogen, Inc. (INGN)
| Market Cap | 173.83M -23.2% |
| Revenue (ttm) | 354.30M +3.2% |
| Net Income | -24.60M |
| EPS | -0.91 |
| Shares Out | 26.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 235,192 |
| Open | 6.25 |
| Previous Close | 6.25 |
| Day's Range | 6.25 - 6.59 |
| 52-Week Range | 5.05 - 9.13 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 12.00 (+83.21%) |
| Earnings Date | Nov 5, 2026 |
About INGN
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airw... [Read more]
Financial Performance
In 2025, Inogen's revenue was $348.67 million, an increase of 3.86% compared to the previous year's $335.71 million. Losses were -$22.75 million, -36.62% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for INGN stock is "Buy." The 12-month stock price target is $12.0, which is an increase of 83.21% from the latest price.
News
Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026.
Inogen to divest U.S. oxygen rental business to Rotech Healthcare
Inogen (INGN) announced that it has signed a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare, a national provider of home respiratory and medical equipment. Under…
Inogen board approves increase of $15M to existing share buyback authorization
Subject to the closing of the Rotech transaction, Inogen’s (INGN) Board of Directors has approved an increase of $15M to the company’s existing share repurchase authorization, bringing the total autho...
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--INOGEN ANNOUNCES DIVESTITURE OF ITS U.S. OXYGEN RENTAL BUSINESS TO ROTECH.
Inogen Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 3% year-over-year to $95.1 million, led by 15% international growth and new product launches. U.S. B2B sales offset DTC and rental declines, while adjusted EBITDA improved 15%. Full-year revenue guidance was lowered, but adjusted EBITDA guidance was raised.
Inogen Earnings release: Q2 2026
Inogen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Inogen Slides: Q2 2026
Inogen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Inogen Quarterly report: Q2 2026
Inogen has published its Q2 2026 quarterly earnings report on August 6, 2026.
Inogen Announces Second Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Reported second quarter revenue of $95.1 million. Company raises full-year adjusted EBITDA guidance to approximately $4.0 million.
Inogen Slides: Corporate presentation
Inogen has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026.
Inogen names Andy Reding COO
Inogen (INGN) announced the appointment of Andy Reding to the newly created role of Chief Operating Officer, effective Monday, July 6, 2026. Mr. Reding will be responsible for driving revenue…
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Andy Reding as Chief Operating Officer.
Inogen Transcript: AGM 2026
Directors and auditors were elected and ratified, executive compensation and the equity plan were approved, but the proposal to declassify the board did not pass. The meeting concluded with a Q&A session addressing forward-looking risks.
Inogen reports Q1 EPS (30c), one estimate (21c)
Reports Q1 revenue $85.1M, two estimates $82.4M. “Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities…
Inogen Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 3.4% year-over-year to $85.1 million, led by 18% international growth, while U.S. sales declined. New product launches and international expansion are expected to drive full-year growth, with profitability improvements anticipated in Q2 and Q3.
Inogen Slides: Q1 2026
Inogen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Inogen Earnings release: Q1 2026
Inogen released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Inogen Quarterly report: Q1 2026
Inogen has published its Q1 2026 quarterly earnings report on May 7, 2026.
Inogen Announces First Quarter 2026 Financial Results
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2026 Financial Results.
Inogen Proxy statement: Proxy filing
Inogen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report First Quarter 2026 Financial Results on May 7, 2026.
Inogen Proxy statement: Proxy filing
Inogen filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Inogen Transcript: 25th Annual Needham Virtual Healthcare Conference
Leadership expansion and strategic hires support transformation into a broader respiratory care platform. New product launches, including Voxi 5, Simeox, and Aurora masks, are expected to drive growth and margin improvement, while B2B channel gains offset DTC headwinds. Share repurchases and disciplined spending reinforce a focus on shareholder value.
Inogen initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of Inogen (INGN) with a Buy rating and $12 price target The firm says Inogen is a respiratory-focused company and home medical equipment provider transitioning from…